Efficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or sex

Journal of Clinical Hypertension

Volumn 12, Issue 1, 2010, Pages 3-13

  Oparil, Suzanne ^a   Pimenta, Eduardo ^b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCHLOROTHIAZIDE; OLMESARTAN; PLACEBO; ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; AGED; AGING; ALGORITHM; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NEGRO; NEUROLOGIC DISEASE; PARALLEL DESIGN; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINGLE BLIND PROCEDURE; UNITED STATES; AGE; COMPARATIVE STUDY; MIDDLE AGED; RACE; RISK ASSESSMENT; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; CONTINENTAL POPULATION GROUPS; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; RISK ASSESSMENT; SEX FACTORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 77949350164     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00217.x     Document Type: Article

References (24)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-e146.
2. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294:466-472.
3. Hertz RP, Unger AN, Cornell JA, et al. Racial disparities in hypertension prevalence, awareness, and management. Arch Intern Med. 2005;165:2098-2104.
4. Franco OH, Peeters A, Bonneux L, et al. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension. 2005;46:280-286.
5. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404.
6. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-1762.
7. Richardson AD, Piepho RW. Effect of race on hypertension and antihypertensive therapy. Int J Clin Pharmacol Ther. 2000;38:75-79.
8. Jamerson K, DeQuattro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med. 1996; 101:22S-32S.
9. Park IU, Taylor AL. Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. Ann Fam Med. 2007;5:444-452.
10. Wassertheil-Smoller S, Psaty B, Greenland P, et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA. 2004;292: 2849-2859.
11. Neutel JM, Gilderman LI. Hypertension control in the elderly. J Clin Hypertens (Greenwich). 2008;1(suppl 1):33-39.
12. Giles TD, Oparil S, Silfani TN, et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007;9:187-195.
13. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3:283-291.
14. Oparil S, Chrysant SG, Kereiakes D, et al. Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. J Clin Hypertens (Greenwich). 2008;10: 911-921.
15. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75.
16. Psaty BM, Manolio TA, Smith NL, et al. Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. Arch Intern Med. 2002;162:2325-2332.
17. Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004;17:252-259.
18. Izzo JL. Jr, Neutel JM, Silfani T, et al. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an openlabel titration study. J Clin Hypertens (Greenwich). 2007;9:36-44.
19. Kereiakes DJ, Neutel JM, Punzi HA, et al. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Am J Cardiovasc Drugs. 2007;7:361-372.
20. Mallion JM, Heagerty A, Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J Hypertens. 2007;25:2168-2177.
21. Zannad F, Fay R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. Fundam Clin Pharmacol. 2007;21:181-190.
22. Noon JP, Trischuk TC, Gaucher SA, et al. The effect of age and gender on arterial stiffness in healthy Caucasian Canadians. J Clin Nurs. 2008;17:2311-2317.
23. O'Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol. 2007;50:1-13.
24. Kereiakes DJ, Neutel J, Stoakes KA, et al. The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in patients aged 65 and older. J Clin Hypertens (Greenwich). 2009;11:411-421.